TAVR Firm JenaValve Nabs Boston Sci Exec As CEO
This article was originally published in The Gray Sheet
Victoria Carr-Brendel, who was running Boston Scientific’s Bayer Interventional business, is the new CEO of transcatheter aortic valve company JenaValve. TAVR startup competitor, Direct Flow Medical, also recently hired a new CEO with large-company medtech pedigree.
You may also be interested in...
Direct Flow Medical hopes it May 7 appointment of Daniel Lemaitre as CEO will elevate its competitive game against larger players in the transcatheter aortic valve replacement market.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.